000K  utf8
1100  2022$c2022-06-10
1500  eng
2050  urn:nbn:de:hbz:465-20231121-151949-4
2051  10.1002/brb3.2662
3000  Nsaka, Michael
3010  Glas, Martin
3010  Holle, Dagny
3010  Kleinschnitz, Christoph
3010  Scheffler, Armin
3010  Schenk, Hannah
3010  Wurthmann, Sebastian
4000  Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies  [Nsaka, Michael]
4209  Background: Current German and European guidelines suggest migraine patients undertake a treatment break after 9 to 12 months of treatment with CGRP (pathway) monoclonal antibodies. Methods: Clinical routine data of highly resistant migraine patients were analyzed before treatment with CGRP monoclonal antibodies (baseline), after 12 months of treatment, and following a treatment break between November 2018 and December 2020 in the West German Headache Centre, University Hospital Essen, Germany. Monthly migraine days (MMD), monthly headache days (MHD), and days of acute medication intake (AMD) were assessed. Results: Complete clinical data from 46 migraine patients (14 episodic migraine (EM), 32 chronic migraine (CM) patients) treated with erenumab (n = 40), galcanezumab (n = 4), and fremanezumab (n = 2) were analyzed. The mean number of MMDs among EM and CM patients after 12 months of CGRP antibody treatment increased during the treatment break by 5.18 (SE 0.92, p < .001) and 5.06 (SE 1.22, p = .003) days, respectively. There was an increased intake of acute medications among episodic (4.72, SE 0.87, p = .004) and chronic migraine patients (3.01, SE 1.08, p = .013) during treatment break. Eighty-three percent of patients (n = 38) were dissatisfied with the mandatory treatment break. All patients continued with a CGRP (pathway) monoclonal antibody after the mandatory treatment break. Conclusion: A mandatory break in CGRP (pathway) monoclonal antibody therapy had a negative short-term impact on migraine patients.
4950  https://doi.org/10.1002/brb3.2662$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:hbz:465-20231121-151949-4$xR$3Volltext$534
4961  https://duepublico2.uni-due.de/receive/duepublico_mods_00078909
5051  610
5550  CGRP (pathway) antibodies
5550  disease modification
5550  guidelines
5550  migraine
5550  one-year prophylactictreatment
5550  treatmentbreak